Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies
Carregando...
Citações na Scopus
63
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Citação
INTERNATIONAL JOURNAL OF CANCER, v.129, n.4, p.920-930, 2011
Resumo
Arg72Pro is a common polymorphism in TP53, showing differences in its biological functions. Case-control studies have been performed to elucidate the role of Arg72Pro in cancer, although the results are conflicting and heterogeneous. Here, we analyzed pooled data from case-control studies to determine the role of Arg72Pro in different cancer sites. We performed a systematic review and meta-analysis of 302 case-control studies that analyzed Arg72Pro in cancer susceptibility. Odds ratios were estimated for different tumor sites using distinct genetic models, and the heterogeneity between studies was explored using I(2) values and meta-regression. We adopted quality criteria to classify the studies. Subgroup analyses were done for tumor sites according to ethnicity, histological, and anatomical sites. Results indicated that Arg72Pro is associated with higher susceptibility to cancer in some tumor sites, mainly hepatocarcinoma. For some tumor sites, quality of studies was associated with the size of genetic association, mainly in cervical, head and neck, gastric, and lung cancer. However, study quality did not explain the observed heterogeneity substantially. Meta-regression showed that ethnicity, allelic frequency and genotyping method were responsible for a substantial part of the heterogeneity observed. Our results suggest ethnicity and histological and anatomical sites may modulate the penetrance of Arg72Pro in cancer susceptibility. This meta-analysis denotes the importance for more studies with good quality and that the covariates responsible for heterogeneity should be controlled to obtain a more conclusive response about the function of Arg72Pro in cancer.
Palavras-chave
Arg72Pro, p53, meta-regression, heterogeneity, cancer susceptibility, meta-analysis, case-control
Referências
- Hong Y, 2005, CANCER RES, V65, P9582, DOI 10.1158/0008-5472.CAN-05-1460
- Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
- Zhou Y, 2007, INT J CANCER, V121, P1481, DOI 10.1002/ijc.22833
- Hainaut P, 2009, LANCET ONCOL, V10, P913, DOI 10.1016/S1470-2045(09)70198-6
- Hu N, 2003, CANCER DETECT PREV, V27, P132, DOI 10.1016/S0361-090X(03)00031-X
- Damin APS, 2006, CANCER DETECT PREV, V30, P523, DOI 10.1016/j.cdp.2006.09.007
- SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8
- Sjalander A, 1996, HUM HERED, V46, P41, DOI 10.1159/000154324
- Achatz MIW, 2009, LANCET ONCOL, V10, P920, DOI 10.1016/S1470-2045(09)70089-0
- Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
- Weston A, 1997, CANCER EPIDEM BIOMAR, V6, P105
- Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302
- Sjalander A, 1996, CARCINOGENESIS, V17, P1313, DOI 10.1093/carcin/17.6.1313
- Pietsch EC, 2006, ONCOGENE, V25, P1602, DOI 10.1038/sj.onc.1209367
- Kalemi TG, 2005, CANCER LETT, V222, P57, DOI 10.1016/j.canlet.2004.11.025
- Yan LL, 2009, INT J CANCER, V125, P2903, DOI 10.1002/ijc.24603
- Tada M, 2001, CARCINOGENESIS, V22, P515, DOI 10.1093/carcin/22.3.515
- Olivier M, 2009, CANCER GENE THER, V16, P1, DOI 10.1038/cgt.2008.69
- Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093
- Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879
- Marin MC, 2000, NAT GENET, V25, P47
- Makni H, 2000, INT J CANCER, V87, P528, DOI 10.1002/1097-0215(20000815)87:4<528::AID-IJC11>3.3.CO;2-F
- Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495
- Dakouras A, 2008, ANTICANCER RES, V28, P1039
- Storey A, 1998, NATURE, V393, P229
- Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584
- Klug SJ, 2009, LANCET ONCOL, V10, P772, DOI 10.1016/S1470-2045(09)70187-1
- Haiman CA, 2006, NEW ENGL J MED, V354, P333, DOI 10.1056/NEJMoa033250
- Baynes C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1669
- BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228
- Borenstein M, 2009, INTRO METAANALYSIS, P450
- BROSH R, 2009, NAT REV CANCER, V10, P701
- Buyru N, 2003, ONCOL REP, V10, P711
- Costa S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-32
- Egger M, 2001, SYSTEMATIC REV HLTH, p[xviii, 487]
- Francisco G, 2008, EUR J HUM GENET, V16, P724, DOI 10.1038/ejhg.2008.6
- Gaudet MM, 2008, BREAST CANCER RES TR, V108, P93, DOI 10.1007/s10549-007-9573-0
- Gochhait S, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1780
- Hrstka R, 2009, J CELL MOL MED, V13, P440, DOI 10.1111/j.1582-4934.2008.00634.x
- Huang Xin-En, 2003, Breast Cancer, V10, P307, DOI 10.1007/BF02967650
- Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159
- Koushik A, 2004, CANCER EPIDEM BIOMAR, V13, P11, DOI 10.1158/1055-9965.EPI-083-3
- Minelli C, 2009, AM J EPIDEMIOL, V170, P1333, DOI 10.1093/aje/kwp350
- Murata M, 1996, CARCINOGENESIS, V17, P261, DOI 10.1093/carcin/17.2.261
- Nadji SA, 2007, LUNG CANCER, V56, P145, DOI 10.1016/j.lungcan.2006.12.006
- Popanda O, 2007, LUNG CANCER, V55, P25, DOI 10.1016/j.lungcan.2006.09.006
- SHAO Y, 2008, DIS ESOPHAGUS, V2, P139
- Szymanowska A, 2006, LUNG CANCER-J IASLC, V52, P9, DOI 10.1016/j.lungcan.2005.12.007
- Tan XL, 2007, PHARMACOGENET GENOM, V17, P639, DOI 10.1097/FPC.0b013e3280d5121c
- Yang WJ, 2008, MOL CARCINOGEN, V47, P100, DOI 10.1002/mc.20368